Dipak S Thorat, Yogesh V Ushir, Sudarshan Singh, Pooja V Nagime
{"title":"A Mini Review on Monkey-Pox: Outbreak, Challenges, and Management Strategies.","authors":"Dipak S Thorat, Yogesh V Ushir, Sudarshan Singh, Pooja V Nagime","doi":"10.2174/0118715265378067250717103733","DOIUrl":null,"url":null,"abstract":"<p><p>Monkeypox (Mpox) has become a significant global health concern, particularly since 2022. It has spread rapidly to numerous locations, and we urgently need to learn more about it. This overview discusses what Mpox is, how it spreads, its effects on people, and the medications that can be used to assist. Between January 2022 and March 2025, approximately 129,523 people were in-fected with Mpox in 120 countries. This demonstrates that HPV has progressed from being passed down from animals to being transmitted between people, including through intimate touch, as in some sexual interactions. Scientists discovered significant alterations in the virus that could help it adapt to people. Currently, we do not have many therapy alternatives. However, certain medications, such as tecovirimat and cidofovir, as well as specific vaccines (such as MVA-BN), can aid in recovery. When administered promptly after exposure, the vaccine is extremely effective in protecting peo-ple. This review emphasizes the importance of detecting Mpox early, monitoring the virus's evolu-tion, and ensuring that people, particularly those who are more susceptible to illness, are immunized. A One Health strategy, which encompasses the care of humans, animals, and the environment in a unified approach, is crucial to preventing future outbreaks. To keep everyone safe, we must prepare for and strengthen our response to Mpox.</p>","PeriodicalId":101326,"journal":{"name":"Infectious disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715265378067250717103733","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Monkeypox (Mpox) has become a significant global health concern, particularly since 2022. It has spread rapidly to numerous locations, and we urgently need to learn more about it. This overview discusses what Mpox is, how it spreads, its effects on people, and the medications that can be used to assist. Between January 2022 and March 2025, approximately 129,523 people were in-fected with Mpox in 120 countries. This demonstrates that HPV has progressed from being passed down from animals to being transmitted between people, including through intimate touch, as in some sexual interactions. Scientists discovered significant alterations in the virus that could help it adapt to people. Currently, we do not have many therapy alternatives. However, certain medications, such as tecovirimat and cidofovir, as well as specific vaccines (such as MVA-BN), can aid in recovery. When administered promptly after exposure, the vaccine is extremely effective in protecting peo-ple. This review emphasizes the importance of detecting Mpox early, monitoring the virus's evolu-tion, and ensuring that people, particularly those who are more susceptible to illness, are immunized. A One Health strategy, which encompasses the care of humans, animals, and the environment in a unified approach, is crucial to preventing future outbreaks. To keep everyone safe, we must prepare for and strengthen our response to Mpox.